Why Route of Administration Matters in Regulatory Review

Route of administration matters in regulatory review because it determines which physical and biological barriers a substance encounters before reaching systemic circulation or a local target. An injected peptide, swallowed peptide, buccal film, nasal formulation, or topical preparation may produce different exposure, metabolism, tissue distribution, local effects, and safety risks even when the active substance has the same name.

Evidence from one route should not automatically be transferred to another. A peptide that produces an effect after direct injection in an animal model may degrade, remain unabsorbed, or create a different exposure profile when administered through an oral mucosal or gastrointestinal route.

Route-specific evaluation is therefore an essential part of the regulatory review of research peptides, alongside identity, formulation, product quality, evidence strength, and safety information.

InStrips products are offered for research and analytical use only. Delivery-route terminology, release from a formulation, laboratory permeability, animal exposure, or blood detection does not establish human absorption, effectiveness, dosage, safety, treatment value, or suitability for human use.

What Is a Route of Administration?

A route of administration describes how a substance or finished product is introduced into or applied to the body.

Routes may include:

• oral ingestion
• buccal administration
• sublingual administration
• nasal administration
• topical application
• transdermal delivery
• subcutaneous injection
• intramuscular injection
• intravenous administration

Each route creates a different sequence of formulation, absorption, distribution, metabolism, and safety questions.

Route Is Part of the Product

A finished drug product is not defined only by its active ingredient.

Its identity also includes characteristics such as:

• strength
• dosage form
• formulation
• release behavior
• route
• packaging
• storage

Changing the route can turn the product into a scientifically and regulatorily different intervention.

Why Peptides Are Sensitive to Route

Peptides are made from amino acids linked through peptide bonds. Depending on their sequence and structure, they may be vulnerable to enzymes, pH conditions, oxidation, hydrolysis, aggregation, and membrane barriers.

Route can influence whether a peptide:

• remains intact
• releases from the dosage form
• crosses a biological membrane
• enters circulation
• reaches a tissue
• is metabolized rapidly
• produces local irritation
• triggers an immune response

Oral Ingestion

A swallowed peptide typically encounters the gastrointestinal system.

Potential barriers include:

• stomach acidity
• digestive proteases
• intestinal peptidases
• mucus
• epithelial membranes
• transport limitations
• first-pass metabolism

A peptide may be broken into smaller fragments or amino acids before substantial intact absorption occurs.

Survival in one in vitro digestive test does not prove predictable human bioavailability.

Buccal Administration

Buccal administration places a formulation against the inner cheek.

The product may interact with:

• saliva
• oral enzymes
• mucus
• mucosal tissue
• mechanical movement
• food or drink residue

Part of the released substance may cross the mucosa, remain in the dosage form, degrade locally, be removed by saliva, or be swallowed.

A film dissolving in the mouth does not prove that its complete active content entered systemic circulation.

Sublingual Administration

Sublingual administration places a formulation beneath the tongue.

The sublingual and buccal tissues differ in thickness, permeability, saliva exposure, available surface area, and retention conditions.

For that reason, evidence from a sublingual formulation should not automatically be used to describe a buccal product, even though both are oral mucosal routes.

Nasal Administration

Nasal formulations encounter the nasal mucosa, mucus, ciliary clearance, local enzymes, and limited administration volume.

Potential considerations include:

• retention time
• particle or droplet distribution
• local irritation
• mucociliary clearance
• swallowed fraction
• systemic absorption
• variability caused by congestion

A proposed connection with the central nervous system does not establish effective or selective delivery to the brain.

Topical and Transdermal Routes

Topical products are generally applied to a local surface, while transdermal products are designed to move an active ingredient across the skin into systemic circulation.

The skin presents a substantial barrier, particularly through the outer stratum corneum.

Relevant variables include:

• molecular size
• charge
• lipid solubility
• skin condition
• contact time
• adhesion
• permeation enhancers
• temperature

Presence on the skin does not prove systemic delivery or penetration into deeper target tissues.

Subcutaneous Injection

Subcutaneous administration places a formulation into tissue beneath the skin.

Absorption can depend on:

• local blood flow
• injection volume
• formulation
• molecular size
• depot formation
• enzymatic degradation
• local tissue reactions

Subcutaneous injection avoids some gastrointestinal barriers but does not guarantee immediate or complete systemic exposure.

Intramuscular Injection

Intramuscular administration places the product into muscle tissue.

Absorption can vary with:

• injection site
• blood flow
• formulation viscosity
• depot characteristics
• particle size
• local tissue condition

An intramuscular formulation may have a different exposure profile from a subcutaneous or intravenous product.

Intravenous Administration

Intravenous administration introduces a substance directly into the bloodstream.

This route avoids an absorption step, but it does not avoid:

• protein binding
• enzymatic degradation in blood
• distribution into off-target tissues
• liver metabolism
• kidney clearance
• immune reactions
• infusion-related effects

Direct bloodstream entry does not guarantee delivery to the desired tissue or cell.

Bioavailability Depends on Route

Bioavailability concerns the extent and sometimes the rate at which an active substance reaches systemic circulation in an interpretable form.

Route may affect:

• the absorbed fraction
• peak concentration
• time to peak concentration
• total exposure
• exposure duration
• metabolite formation

Two routes can deliver the same nominal amount while producing very different blood concentrations and biological effects.

Administered Amount Is Not Systemic Exposure

The amount placed into a capsule, strip, spray, patch, or syringe does not by itself show how much intact substance reaches circulation.

Between administration and systemic exposure, the product may undergo:

• incomplete release
• chemical degradation
• enzymatic breakdown
• poor permeability
• local retention
• first-pass metabolism

Systemic Exposure Is Not Tissue Exposure

A detectable blood concentration does not prove that the peptide reaches an intended organ or tissue at an effective concentration.

Distribution can be influenced by:

• blood flow
• capillary permeability
• protein binding
• molecular size
• charge
• transporters
• tissue barriers
• clearance

Target-tissue exposure requires separate evidence.

Tissue Exposure Is Not Target Engagement

A substance may enter a tissue without reaching the relevant cells or interacting with the intended molecular target.

Target engagement may depend on:

• cellular uptake
• receptor availability
• intracellular stability
• concentration
• duration
• competition with other molecules

Even verified target engagement does not automatically establish clinical benefit.

Route Can Change Safety

Different routes can create different risks.

Examples may include:

• gastrointestinal effects after oral use
• oral mucosal irritation after buccal exposure
• nasal irritation after intranasal administration
• skin reactions after topical use
• infection or tissue injury after injection
• rapid systemic reactions after intravenous exposure

A route considered tolerable for one formulation cannot automatically be assumed safe for a different substance or concentration.

Route Can Change Immunogenicity Questions

Peptides and peptide-related impurities can potentially interact with the immune system.

Immune risk may be influenced by:

• route
• aggregation
• impurities
• dose frequency
• exposure duration
• formulation components
• patient factors

Safety information from limited exposure through one route may not predict repeated exposure through another.

Formulation and Route Must Be Considered Together

Route does not operate independently from formulation.

An oral mucosal film may use polymers, buffers, sweeteners, stabilizers, or permeation enhancers. An injection may use salts, buffers, preservatives, or depot-forming components.

These ingredients can affect:

• release
• stability
• absorption
• local tolerance
• microbial quality
• systemic exposure

This is why formulation-specific evidence is required rather than assuming the active-substance name determines product behavior.

Why Animal Injection Studies May Not Support Oral Claims

Many preclinical peptide studies use injection because it provides controlled exposure and avoids some biological barriers.

If a commercial or compounded product uses an oral or buccal route, reviewers still need evidence concerning:

• release
• stability after hydration
• barrier permeability
• swallowed fraction
• systemic exposure
• metabolites
• tissue distribution

An injected animal finding cannot independently establish a human outcome from an oral film.

Why Studies Must Report the Route Clearly

A study report should define:

• route
• dosage form
• formulation
• administered amount
• frequency
• duration
• sampling times

Without this information, exposure and outcome results may be difficult to reproduce or compare.

Route in Section 503A Review

When FDA evaluates a nominated bulk drug substance, the proposed compounded routes form part of the regulatory context.

The assessment may ask whether the available evidence concerns:

• the same route proposed by the nominator
• a comparable dosage form
• a relevant exposure level
• the same molecular form
• similar safety conditions

The process of evaluating evidence during a peptide review therefore includes matching studies to the proposed route rather than treating all administration methods as equivalent.

How Route Claims Become Misleading

Potentially misleading statements may claim that one route:

• completely bypasses degradation
• guarantees direct bloodstream entry
• provides injection-like exposure
• delivers the substance to a specific tissue
• works faster because the dosage form dissolves quickly
• is safer because it avoids needles

These claims require direct product-specific evidence.

Questions Regulators May Ask

Route-specific review may consider:

• Does the formulation release the intended substance?
• Does the peptide remain intact?
• What fraction is absorbed?
• What fraction is swallowed or lost?
• What concentrations appear in blood?
• Which metabolites form?
• Which tissues receive exposure?
• What local reactions occur?
• What systemic adverse effects occur?
• Does the route match the evidence cited?

Final Perspective

Route of administration changes the scientific meaning of peptide evidence. Swallowed, buccal, sublingual, nasal, topical, subcutaneous, intramuscular, and intravenous products encounter different barriers and produce different exposure patterns.

The same peptide name does not make studies interchangeable across routes. Release, degradation, absorption, systemic exposure, tissue distribution, target engagement, local tolerance, and safety must be examined for the actual formulation and route being considered.

Regulatory conclusions should therefore remain route-specific rather than extending an injected laboratory or animal result to an untested oral, mucosal, nasal, topical, or other product.